<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900900</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00008225</org_study_id>
    <nct_id>NCT00900900</nct_id>
  </id_info>
  <brief_title>The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers</brief_title>
  <acronym>DHEA</acronym>
  <official_title>The Effects of One-Time Pregnenolone, DHEA, Or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jed E. Rose</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the potential therapeutic value of two neurosteroid treatments (DHEA
      and pregnenolone) in the treatment of tobacco withdrawal symptoms. This will include
      assessing whether these agents relieve craving for cigarettes elicited by exposure to a
      mildly stressful cognitive task. Pregnenolone (400 mg orally), DHEA (400 mg orally) and
      placebo will be administered one at each of the three sessions in a randomized order.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The administration of DHEA or pregnenolone will reduce smoking withdrawal symptoms.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The administration of DHEA or pregnenolone will reduce the subjective rewarding effects of nicotine inhaled in cigarette smoke.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The administration of DHEA or pregnenolone will reduce stress-induced changes in mood and craving for cigarettes.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Substance Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>Dehydroepiandrosterone (DHEA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnenolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dehydroepiandrosterone (DHEA)</intervention_name>
    <description>one-time 400mg oral dose of DHEA</description>
    <arm_group_label>Dehydroepiandrosterone (DHEA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>pregnenolone</intervention_name>
    <description>one-time 400mg oral dose of pregnenolone</description>
    <arm_group_label>Pregnenolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one-time dose oral dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male;

          2. 18-65 years old;

          3. smoked an average of at least 10 cigarettes per day for three cumulative or continuous
             years of a brand that delivers (by Federal Trade Commission rated yields) at least 0.5
             mg nicotine;

          4. afternoon expired carbon monoxide reading of at least 10 ppm;

          5. in general good health, based on physical examination, EKG serum chemistries, CBC and
             urinalysis.

        Exclusion Criteria:

          1. Participants must not have uncontrolled hypertension (systolic &gt;140 mm Hg, diastolic
             &gt;95 mm Hg)

          2. hypotension (systolic &lt;90 mm Hg, diastolic &lt;60 mm Hg);

          3. coronary heart disease;

          4. heart attack;

          5. cardiac rhythm disorder (irregular heart rhythm);

          6. chest pains (unless history, exam, and EKG clearly indicate a non-cardiac source);

          7. cardiac (heart) disorder (including but not limited to valvular heart disease, heart
             murmur, heart failure);

          8. liver or kidney disorder (except kidney stones, gallstones);

          9. gastrointestinal problems or disease other than gastroesophageal reflux,

         10. heartburn, or irritable bowel syndrome;

         11. ulcers within the past 6 months;

         12. lung disorder (including but not limited to COPD, emphysema, and asthma);

         13. brain abnormality (including but not limited to, stroke, brain tumor, seizure
             disorder);

         14. history of fainting;

         15. problems giving blood samples;

         16. diabetes;

         17. current cancer or treatment for cancer in the past 6 months (except basal or squamous
             cell skin cancer);

         18. other major medical condition;

         19. major depression, panic disorder, anxiety, bipolar disorder, schizophrenia, risk of
             suicide, or substance dependence other than nicotine dependence;

         20. subjects who endorse suicidal ideation on the MINI abridged;

         21. alcohol or drugs abuse;

         22. reported use of illicit drugs within the past 30 days, or if the drug screen is
             positive;

         23. reported use of smokeless tobacco (chewing tobacco, snuff), cigars, pipes, or nicotine
             replacement therapy; testosterone replacement therapy, DHEA or Pregnenolone;
             experimental (investigational) drugs; psychiatric medications (including
             antidepressants, anti-anxiety agents. anti-psychotics), sleep aids, medications that
             increase DHEA and/or DHEA-S concentrations (including, but not limited to: diltiazem,
             benfluorex, amlodipine, alprazolam, danazol, metformin, nitrendipine and retinol), or
             any other medications that are known to affect smoking (e.g. clonidine, muscle
             relaxants, opiate pain medications) within the past 2 weeks.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jed E Rose, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Marx, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Center for Nicotine &amp; Smoking Cessation Research</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Center for Nicotine &amp; Smoking Cessation Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <disposition_first_submitted>September 10, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>September 14, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 21, 2012</disposition_first_posted>
  <last_update_submitted>September 14, 2012</last_update_submitted>
  <last_update_submitted_qc>September 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Jed E. Rose</investigator_full_name>
    <investigator_title>Professor Department of Psychiatry and Behavorial Sciences</investigator_title>
  </responsible_party>
  <keyword>Cigarette Smokers</keyword>
  <keyword>DHEA</keyword>
  <keyword>dehydroepiandrosterone</keyword>
  <keyword>pregnenolone</keyword>
  <keyword>Nicotine withdrawal symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

